701232-18-0 Usage
Uses
Used in Pharmaceutical Industry:
4-[4-(2-BROMO-2-METHYL-1-OXOPROPYL)PHENYL]-CYCLOHEXANEACETIC ACID ETHYL ESTER is used as an analgesic and anti-inflammatory agent for managing conditions characterized by pain and inflammation, such as osteoarthritis and rheumatoid arthritis. Its application in this industry is due to its ability to effectively reduce inflammation and alleviate pain, improving the quality of life for patients suffering from these conditions.
Used in Pain Management:
4-[4-(2-BROMO-2-METHYL-1-OXOPROPYL)PHENYL]-CYCLOHEXANEACETIC ACID ETHYL ESTER is utilized as a pain reliever for acute pain, such as that resulting from injuries or post-surgical recovery. Its use in pain management is attributed to its capacity to target and reduce the chemicals responsible for pain sensation.
Used in Gynecological Applications:
4-[4-(2-BROMO-2-METHYL-1-OXOPROPYL)PHENYL]-CYCLOHEXANEACETIC ACID ETHYL ESTER is employed as a treatment for menstrual cramps, providing relief from the discomfort associated with menstruation. Its application in gynecology is due to its effectiveness in reducing the inflammation and pain associated with dysmenorrhea.
Check Digit Verification of cas no
The CAS Registry Mumber 701232-18-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,0,1,2,3 and 2 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 701232-18:
(8*7)+(7*0)+(6*1)+(5*2)+(4*3)+(3*2)+(2*1)+(1*8)=100
100 % 10 = 0
So 701232-18-0 is a valid CAS Registry Number.
InChI:InChI=1/C20H27BrO3/c1-4-24-18(22)13-14-5-7-15(8-6-14)16-9-11-17(12-10-16)19(23)20(2,3)21/h9-12,14-15H,4-8,13H2,1-3H3
701232-18-0Relevant academic research and scientific papers
Discovery of 6-phenylpyrimido[4,5- B ][1,4]oxazines as potent and selective Acyl CoA: Diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents
Fox, Brian M.,Sugimoto, Kazuyuki,Iio, Kiyosei,Yoshida, Atsuhito,Zhang, Jian,Li, Kexue,Hao, Xiaolin,Labelle, Marc,Smith, Marie-Louise,Rubenstein, Steven M.,Ye, Guosen,McMinn, Dustin,Jackson, Simon,Choi, Rebekah,Shan, Bei,Ma, Ji,Miao, Shichang,Matsui, Takuya,Ogawa, Nobuya,Suzuki, Masahiro,Kobayashi, Akio,Ozeki, Hidekazu,Okuma, Chihiro,Ishii, Yukihito,Tomimoto, Daisuke,Furakawa, Noboru,Tanaka, Masahiro,Matsushita, Mutsuyoshi,Takahashi, Mitsuru,Inaba, Takashi,Sagawa, Shoichi,Kayser, Frank
supporting information, p. 3464 - 3483 (2014/05/20)
The discovery and optimization of a series of acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors based on a pyrimido[4,5-b][1,4]oxazine scaffold is described. The SAR of a moderately potent HTS hit was investigated resulting in the discovery of phenylcyclohexylacetic acid 1, which displayed good DGAT1 inhibitory activity, selectivity, and PK properties. During preclinical toxicity studies a metabolite of 1 was observed that was responsible for elevating the levels of liver enzymes ALT and AST. Subsequently, analogues were synthesized to preclude the formation of the toxic metabolite. This effort resulted in the discovery of spiroindane 42, which displayed significantly improved DGAT1 inhibition compared to 1. Spiroindane 42 was well tolerated in rodents in vivo, demonstrated efficacy in an oral triglyceride uptake study in mice, and had an acceptable safety profile in preclinical toxicity studies.
